BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 27537859)

  • 1. Emerging drugs for the treatment of kidney disease-induced anemia.
    Malyszko J; Malyszko JS
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):315-30. PubMed ID: 27537859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigational therapies for renal disease-induced anemia.
    Schmid H; Jelkmann W
    Expert Opin Investig Drugs; 2016 Aug; 25(8):901-16. PubMed ID: 27122198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
    Mima A
    Eur J Pharmacol; 2021 Dec; 912():174583. PubMed ID: 34678238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Will there still be a role for the originator erythropoiesis-simulating agents after the biosimilars and the hypoxia-inducible factor stabilizers approval?
    Locatelli F; Del Vecchio L
    Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):339-344. PubMed ID: 29846220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
    Del Vecchio L; Locatelli F
    Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis.
    Rainville N; Jachimowicz E; Wojchowski DM
    Expert Opin Ther Targets; 2016; 20(3):287-301. PubMed ID: 26419263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepcidin as a therapeutic target for anemia and inflammation associated with chronic kidney disease.
    Malyszko J; Malyszko JS; Matuszkiewicz-Rowinska J
    Expert Opin Ther Targets; 2019 May; 23(5):407-421. PubMed ID: 30907175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and future chemical therapies for treating anaemia in chronic kidney disease.
    Locatelli F; Del Vecchio L; Luise MC
    Expert Opin Pharmacother; 2017 Jun; 18(8):781-788. PubMed ID: 28443351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease.
    Hasegawa S; Tanaka T; Nangaku M
    Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):331-338. PubMed ID: 30067604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Treatment Approaches for the Anemia of CKD.
    Bonomini M; Del Vecchio L; Sirolli V; Locatelli F
    Am J Kidney Dis; 2016 Jan; 67(1):133-42. PubMed ID: 26372086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anemia in conventional hemodialysis: Finding the optimal treatment balance.
    Hasegawa T; Koiwa F; Akizawa T
    Semin Dial; 2018 Nov; 31(6):599-606. PubMed ID: 29909605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. It's time to compare anemia management strategies in hemodialysis.
    Coyne DW
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):740-2. PubMed ID: 20299363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease.
    Kaplan JM; Sharma N; Dikdan S
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29382128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Masters of Erythropoiesis: Hypoxia Inducible Factors and Recent Advances in Anemia of Renal Disease.
    Solak Y; Cetiner M; Siriopol D; Tarim K; Afsar B; Covic A; Kanbay M
    Blood Purif; 2016; 42(2):160-7. PubMed ID: 27318465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies.
    Del Vecchio L; Locatelli F
    Expert Rev Hematol; 2014 Aug; 7(4):495-506. PubMed ID: 25025373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic kidney disease-associated anemia: new remedies.
    Del Vecchio L; Cavalli A; Tucci B; Locatelli F
    Curr Opin Investig Drugs; 2010 Sep; 11(9):1030-8. PubMed ID: 20730698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New alternatives in anemia treatment: biosimilars and HIF stabilizers.
    Krishnan M; Nissenson AR
    Nephrol News Issues; 2014 May; 28(6):24-8. PubMed ID: 24908823
    [No Abstract]   [Full Text] [Related]  

  • 19. Emerging drugs for treatment of anemia of chronic kidney disease.
    Magwood JS; Lebby A; Chen B; Kessler S; Norris L; Bennett CL
    Expert Opin Emerg Drugs; 2013 Dec; 18(4):421-9. PubMed ID: 24033253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pathogenesis and treatment of anemia in chronic kidney disease].
    Nangaku M
    Rinsho Ketsueki; 2017; 58(10):1860-1863. PubMed ID: 28978825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.